PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
5.92%
Revenue growth exceeding 1.5x Medical - Pharmaceuticals median of 0.11%. Joel Greenblatt would investigate if growth quality matches quantity.
6.02%
Cost growth exceeding 1.5x Medical - Pharmaceuticals median of 1.27%. Jim Chanos would check for structural cost disadvantages.
5.52%
Growth of 5.52% versus flat Medical - Pharmaceuticals gross profit. Walter Schloss would verify quality.
-0.38%
Margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate competitive position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-18.09%
Other expenses reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
-0.12%
Operating expenses reduction while Medical - Pharmaceuticals median is 2.01%. Seth Klarman would investigate advantages.
4.98%
Total costs growth exceeding 1.5x Medical - Pharmaceuticals median of 2.27%. Jim Chanos would check for waste.
-4.55%
Interest expense reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
-16.97%
D&A reduction while Medical - Pharmaceuticals median is 2.25%. Seth Klarman would investigate efficiency.
29.37%
EBITDA growth while Medical - Pharmaceuticals declines. Peter Lynch would examine advantages.
22.14%
Margin change of 22.14% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
35.99%
Operating income growth while Medical - Pharmaceuticals declines. Peter Lynch would examine advantages.
28.39%
Margin change of 28.39% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
-11.27%
Other expenses reduction while Medical - Pharmaceuticals median is 13.09%. Seth Klarman would investigate advantages.
29.53%
Income change of 29.53% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
22.29%
Margin change of 22.29% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
28.02%
Tax expense change of 28.02% versus flat Medical - Pharmaceuticals. Walter Schloss would verify strategy.
30.23%
Income change of 30.23% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
22.94%
Margin change of 22.94% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
30.21%
EPS growth exceeding 1.5x Medical - Pharmaceuticals median of 2.22%. Joel Greenblatt would investigate advantages.
30.21%
Diluted EPS growth exceeding 1.5x Medical - Pharmaceuticals median of 2.22%. Joel Greenblatt would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.